Current status and future prospects of yellow fever vaccines

Expert Review of Vaccines

Volumn 14, Issue 11, 2015, Pages 1479-1492

  Beck, Andrew S ^a   Barrett, Alan D T ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

empiric; empiric vaccine; flavivirus; live attenuated; primary seed; rational vaccine; recombinant vaccine; secondary seed; vaccine; viral diversity; yellow fever virus

Indexed keywords

YELLOW FEVER VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; RECOMBINANT VACCINE;

COMPUTER MODEL; DRUG MONITORING; DRUG SAFETY; GENOTYPE; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS STRAIN; YELLOW FEVER VIRUS; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; TRENDS; YELLOW FEVER;

DRUG DISCOVERY; HUMANS; JAPANESE ENCEPHALITIS VACCINES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84945437519     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1083430     Document Type: Review

References (97)

1. Vainio J, Cutts F. Yellow fever. World Health Organization; Geneva: 1998
2. Bazin H. Yellow fever vaccine. Vaccinations: A History. John Libbey Eurotext, Montrouge, France; 2011. p. 407-54
3. World Health Organization. WHO-recommended standards for surveillance of selected vaccine preventable diseases. 2003
4. Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. Trans R Soc Trop Med Hyg 2014; 108: 482-7
5. Burlaud-Gaillard J, Sellin C, Georgeault S, et al. Correlative scanning-transmission electron microscopy reveals that a chimeric flavivirus is released as individual particles in secretory vesicles. PLoS One 2014; 9: e93573
6. Monath TP, Gershman M, Staples JE, Barrett ADT. Yellow fever vaccine. In: Plotkin S.,. editor. Vaccines. Sixth edition. Elsevier, Inc; 2013. p. 870-15
7. Jentes ES, Poumerol G, Gershman MD, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO working group on geographic risk for yellow fever. Lancet Infect Dis 2011; 11: 622-32
8. Stokes A, Bauer JH, Hudson NP. Experimental transmission of yellow fever to laboratory animals. Am J Trop Med Hyg 1928; 1: 103-64
9. Theiler M. Susceptibility of white mice to the virus of yellow fever. Science; New York, NY: 1930. p. 71-367
10. Theiler M. Neutralization tests with immune yellow fever sera and a strain of yellow fever virus adapted to mice. Ann Trop Med Parasitol 1931; 25: 69-77
11. Sellards AW, Hindle E. The preservation of yellow fever virus. Br Med J 1928; 1: 713-14
12. Theiler M. Studies on the action of yellow fever virus in mice. Ann trop Med Parasit 1930; 24: 249-72
13. Durieux C. Preparation of yellow fever vaccine at the Institut Pasteur, Dakar. In: Smithburn KC, Duriex C, Koerber R, et al. editors. YF Vaccination Monograph Series. World Health Organization; Geneva: 1956. p. 31
14. Lloyd W, Penna HA. Studies on the pathogenesis of neurotropic yellow fever virus in Macacus rhesus. Am J Trop Med Hyg 1933; 8: 1-45
15. Ni H, Ryman KD, Wang H, et al. Interaction of yellow fever virus French neurotropic vaccine strain with monkey brain: characterization of monkey brain membrane receptor escape variants. J Virol 2000; 74: 2903-6
16. Sawyer WA, Kitchen SF, Lloyd W. Vaccination against yellow fever with immune serum and virus fixed for mice. J Experimen Med 1932; 55: 945-69
17. Stones PB, Macnamarra FN. Encephalitis following neurotropic yellow fever vaccine administered by scarification in Nigeria: epidemiological and laboratory studies. Trans R Soc Trop Med Hyg 1955; 49: 176-86
18. Wang E, Ryman KD, Jennings AD, et al. Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. J Gen Virol 1995; 76 (Pt 11): 2749-55
19. Theiler M, Smith HH. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J Experimen Med 1937; 65: 767-86
20. Whitman L. Failure of Aedes aegypti to transmit yellow fever cultured virus (17D). Am J Trop Med 2015; 19: 19-26
21. Miller BR, Adkins D. Biological characterization of plaque-size variants of yellow fever virus in mosquitoes and mice. Acta Virol 1988; 32: 227-34
22. United Nations Relief and Rehabilitation Administration. Report to the UNRAA expert commission on quarantine: Dakar yellow-fever vaccine. 2014. p. 618-37
23. Stuart G. The problem of mass vaccination against yellow fever. World Health Organization; Geneva: 1953. p. 1-13
24. World Health Organization. Standards for the manufacture and control of yellow fever vaccine. World Health Organ Epidemiol Bull. Volume 1 World Health Organization; Geneva: 1945. p. 365-70
25. Barrett AD, Teuwen DE. Yellow fever vaccine-how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol 2009; 21: 308-13
26. Garske T, Van Kerkhove MD, Yactayo S, et al. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med 2014; 11: e1001638
27. GAVI. Yellow fever supply and procurement roadmap. Available from: http://www.gavi.org/library/gavi-documents/supply-procurement/yellow-fever-roadmap-public-summary/. [Last accessed 18 June 2015]
28. Roukens AH, Vossen AC, Bredenbeek PJ, et al. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS One 2008; 3: e1993
29. Roukens AH, Vossen AC, van Dissel JT, Visser LG. Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy. Vaccine 2009; 27: 2408-9
30. WHO Expert Committee on Biological Standardization. Recommendations to assure the quality, safety, and efficacy of live attenuated yellow fever vaccines. Volume 978 World Health Organization Technical Report Series; Geneva: 2013. p. 241-314
31. Bres P, Koch M. Production and testing of the WHO yellow fever virus primary seed lot 213-77 and reference batch 168-73. In: Standardization WECoB.,. editor. World health organization technical report series. Volume 36 World Health Organization; Geneva: 1987. p. 113-41
32. Hahn CS, Dalrymple JM, Strauss JH, Rice CM. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad Sci USA 1987; 84: 2019-23
33. dos Santos CN, Post PR, Carvalho R, et al. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res 1995; 35: 35-41
34. Stock NK, Boschetti N, Herzog C, et al. The phylogeny of yellow fever virus 17D vaccines. Vaccine 2012; 30: 989-94
35. Catteau A. Dengue virus M protein contains a proapoptotic sequence referred to as ApoptoM. J Gen Virol 2003; 84: 2781-93
36. Lee E, Lobigs M. E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J Virol 2008; 82: 6024-33
37. Muñoz-Jordán JL, Laurent-Rolle M, Ashour J, et al. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 2005; 79: 8004-13
38. McElroy KL, Tsetsarkin KA, Vanlandingham DL, Higgs S. Manipulation of the yellow fever virus non-structural genes 2A and 4B and the 3non-coding region to evaluate genetic determinants of viral dissemination from the Aedes aegypti midgut. Am J Trop Med Hyg 2006; 75: 1158-64
39. Huang Y-JS, Nuckols JT, Horne KM, et al. Mutagenesis analysis of T380R mutation in the envelope protein of yellow fever virus. Virol J 2014; 11: 1-4
40. Minor PD. Neurovirulence tests of three 17D yellow fever vaccine strains. Biologicals 2011; 39: 167-70
41. Lang J, Zuckerman J, Clarke P, et al. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med Hyg 1999; 60: 1045-50
42. Belmusto-Worn VE, Sanchez JL, McCarthy K, et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 2005; 72: 189-97
43. Camacho LAB. Freire MdS, Leal MdLF, et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 2004; 38: 671-8
44. Camacho LAB, Aguiar SG, Freire MdS, et al. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. Rev Saude Publica 2005; 39: 413-20
45. Pfister M, Kürsteiner O, Hilfiker H, et al. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg 2005; 72: 339-46
46. Ripoll C, Ponce A, Wilson MM, et al. Evaluation of two yellow fever vaccines for routine immunization programs in Argentina. Hum Vaccin 2014; 4: 121-6
47. Rice CM, Grakoui A, Galler R, Chambers TJ. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. N Biolog 1989; 1: 285-96
48. Bonaldo MC, Garratt RC, Marchevsky RS, et al. Attenuation of Recombinant Yellow Fever 17D Viruses Expressing Foreign Protein Epitopes at the Surface. J Virol 2005; 79: 8602-13
49. Nogueira RT, Nogueira AR, Pereira MCS, et al. Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi. PLoS One 2013; 8: e59347
50. Bonaldo MC, Martins MÂ, Rudersdorf R, et al. Recombinant Yellow Fever Vaccine Virus 17D Expressing Simian Immunodeficiency Virus SIVmac239 Gag Induces SIV-Specific CD8+ T-Cell Responses in Rhesus Macaques. J Virol 2010; 84: 3699-706
51. Bredenbeek PJ, Molenkamp R, Spaan WJM, et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 2006; 345: 299-304
52. Bray M, Lai CJ. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc Nat Acad Sci USA 1991; 88: 10342-6
53. Guy B, Barrere B, Malinowski C, et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011; 29: 7229-41
54. ®: a Yellow fever virus-based novel Japanese encephalitis vaccine. Expert Rev Vaccines 2010; 9: 1371-84
55. Capeding MR, Tran NH, Hadinegoro SRS, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase III, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384: 1358-65
56. Villar L, Dayan GH, Arredondo-García JL, et al. Efficacy of a tetravalent dengue vaccine in children in latin America. N Eng J Med 2015; 372: 113-23
57. Monath TP, Liu J, Kanesa-Thasan N, et al. A live, attenuated recombinant West Nile virus vaccine. Proc Nat Acad Sci USA 2006; 103: 6694-9
58. Biedenbender R, Bevilacqua J, Gregg AM, et al. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infec Dis 2011; 203: 75-84
59. Rumyantsev AA, Goncalvez AP, Giel-Moloney M, et al. Single-dose vaccine against tick-borne encephalitis. Proc Nat Acad Sci 2013; 110: 13103-8
60. DeSilva M, Sharma A, Staples E, et al. Notes from the field: fatal yellow fever vaccine-associated viscerotropic disease-Oregon, September 2014. MMWR Morb Mortal Week Report 2015; 64: 279-81
61. Gershman MD, Staples JE, Bentsi-Enchill AD, et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2012; 30: 5038-58
62. Whittembury A, Ramirez G, Hernández H, et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009; 27: 5974-81
63. Monath TP, Cetron MS, McCarthy K, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 2005; 1: 207-14
64. Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the advisory committee on immunization practices (ACIP). In: Shaw F.,. editor, Morbidity and Mortality Weekly Report. Centers for Disease Control and Prevention (CDC), Atlanta; 2010; 59: 1-27
65. Meier KC, Gardner CL, Khoretonenko MV, et al. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog 2009; 5: e1000614
66. Erickson AK, Pfeiffer JK. Dynamic Viral Dissemination in Mice Infected with Yellow Fever Virus Strain 17D. J Virol 2013; 87: 12392-7
67. Roukens AH, Soonawala D, Joosten SA, et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS One 2011; 6: e27753-6
68. Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infec Dis 2008; 198: 500-7
69. Monath TP, Lee CK, Julander JG, et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 2010; 28: 3827-40
70. Monath TP, Fowler E, Johnson CT, et al. An inactivated cell-culture vaccine against yellow fever. N Eng J Med 2011; 364: 1326-33
71. Gaspar LP, Mendes YS, Yamamura AMY, et al. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods 2008; 150: 57-62
72. Pereira RC, Silva ANMR, Souza MCO, et al. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures. Vaccine 2015. [Epub ahead of print]
73. Pincus S, Mason PW, Konishi E, et al. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 1992; 187: 290-7
74. Schäfer B, Holzer GW, Joachimsthaler A, et al. Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. PLoS One 2011; 6: e24505
75. Maciel M, Cruz FdSP, Cordeiro MT, et al. A DNA vaccine against yellow fever virus: development and evaluation. PLoS Negl Trop Dis 2015; 9: e0003693
76. Findlay GM, Clarke LP. Reconversion of the neurotropic into the viscerotropic strain of yellow fever virus in rhesus monkeys. Trans R Soc Trop Med Hyg 1935; 28: 579-600
77. Soper FL, Smith HH. Vaccination with virus 17D in the control of jungle yellow fever in Brazil. In: Transactions of the Third International Congress of Tropical Medicine and Malaria. C.A. Spin & Zoon N.V., Holland; 1938: 295-313
78. Freire MS, Mann GF, Marchevsky RS, et al. Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity. Vaccine 2005; 23: 2501-12
79. Beasley DWC, Morin M, Lamb AR, et al. Adaptation of yellow fever virus 17D to Vero cells is associated with mutations in structural and non-structural protein genes. Virus Res 2013; 1-5
80. Neverov A, Chumakov K. Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines. Proc Natl Acad Sci USA 2010; 107: 20063-8
81. Andino R, Domingo E. Viral quasispecies. Virology 2015; 479-480C: 46-51
82. Victoria JG, Wang C, Jones MS, et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol 2010; 84: 6033-40
83. Beck A, Tesh RB, Wood TG, et al. Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing. J Infec Dis 2014; 209: 334-44
84. Assembly WH. International health regulations (2005). World Health Organization; Geneva: 2006
85. World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2013-conclusions and recommendations. Wkly Epidemiol Rec 2013; 88: 201-6
86. Centers for Disease Control and Prevention(CDC). Advisory committee on immunization practices (ACIP). Summary Report 26 February 2015, Atlanta, GA. 2015. p. 1-72
87. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 2013; 89: 434-44
88. Niedrig M, Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Inter health 1999; 4: 867-71
89. Mudd PA, Piaskowski SM, Neves PCC, et al. The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques-implications for recombinant vaccine design. Immunogenetics 2010; 62: 593-600
90. Julander JG, Trent DW, Monath TP. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine 2011; 29: 6008-16
91. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2008; 10: 116-25
92. Li S, Rouphael N, Duraisingham S, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 2014; 15: 195-204
93. Gaucher D, Therrien R, Kettaf N, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Experim Med 2008; 205: 3119-31
94. Akondy RS, Johnson PLF, Nakaya HI, et al. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc Nat Acad Sci 2015; 112: 3050-5
95. Campi-Azevedo AC, de Araújo-Porto LP, Luiza-Silva M, et al. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children. PLoS One 2012; 7: e49828
96. Neves PCC, Rudersdorf RA, Galler R, et al. CD8+ gamma-delta TCR+ and CD4+ T cells produce IFN-γ at 5-7 days after yellow fever vaccination in Indian rhesus macaques, before the induction of classical antigen-specific T cell responses. Vaccine 2010; 28: 8183-8
97. Neves PCC, Santos JR, Tubarão LN, et al. Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses. PLoS One 2013; 8: e81953